A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of RDX-002 on Postprandial Triglycerides in Patients Discontinuing the Glucagon-like Peptide-1 (GLP-1) Agonists, Semaglutide or Tirzepatide, for the Treatment of Obesity
Latest Information Update: 21 Oct 2024
At a glance
- Drugs RDX-002 (Primary)
- Indications Weight gain
- Focus Pharmacokinetics
- Sponsors Response Pharmaceuticals
- 18 Oct 2024 According to a Response Pharmaceuticals, Inc media release, data from this study are expected in the second half of 2025.
- 18 Oct 2024 According to a Response Pharmaceuticals, Inc media release, company today announced initiation of enrollment (Enrollment of First Patients) in a Phase 2 trial evaluating RDX-002, for post-GLP-1 weight rebound.
- 17 Oct 2024 New trial record